Dr Shah discusses a study of the effect of immune checkpoint inhibitors on patients with cancer and preexisting neurologic autoimmune diseases.
Back
Assessing the Feasibility of Checkpoint Inhibition in Patients With Cancer and Pre-Existing Neurologic Autoimmune Disorders
Shailee S. Shah, MD, discusses the feasibility of using immune checkpoint inhibitors in patients with cancer and neurologic autoimmune disorders.
Assessing the Feasibility of Checkpoint Inhibition in Patients With Cancer and Pre-Existing Neurologic Autoimmune Disorders
Episodes
All
All
A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.
Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.
Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Elfetabart Drozuntecan Elicits 70% ORR Across Lines of Therapy in SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
4
Perioperative Atezolizumab Plus Chemotherapy Extends EFS in Resectable NSCLC
5